This script search US Code. View Rule
Menu Item - Home
Menu Item - Agenda Main page
Menu Item - Historical Agenda
Menu Item - Historical Agenda
Menu Item - Agenda Search
Menu Item - EO Dashboard
Menu Item - Reg Review
Menu Item - EO Agency lists
Menu Item - EO Search
Menu Item - EO Historical Reports
Menu Item - Review Counts
Menu Item - OIRA Letters
Menu Item - EOM 12866 Search
Menu Item - EO XML Reports
Menu Item - ICR Dashboard page
Menu Item - ICR Main page
Menu Item - ICR Search
Menu Item - ICR XML Reports
Menu Item - FAQ
Menu Item - Additional Resources
Menu Item - Contact Us
Search: Agenda Reg Review ICR
       Search

View Rule

View EO 12866 Meetings Printer-Friendly Version     Download RIN Data in XML

HHS/FDA RIN: 0910-AB28 Publication ID: Fall 2004 
Title: Current Good Tissue Practice for Human Cell, Tissue, and Cellular and Tissue-Based Product Establishments; Inspection and Enforcement 
Abstract: The Food and Drug Administration (FDA) is requiring human cell, tissue, and cellular and tissue-based product (HCT/P) establishments to follow current good tissue practice (CGTP), which governs the methods used in, and the facilities and controls used for, the manufacture of HCT/Ps, recordkeeping, and the establishment of a quality program. FDA is also issuing regulations pertaining to labeling, reporting, inspections, and enforcement. 
Agency: Department of Health and Human Services(HHS)  Priority: Other Significant 
RIN Status: Previously published in the Unified Agenda Agenda Stage of Rulemaking: Final Rule Stage 
Major: No  Unfunded Mandates: No 
CFR Citation: 21 CFR 16; 21 CFR 1270; 21 CFR 1271 
Legal Authority: 42 USC 216; 42 USC 243; 42 USC 263a; 42 USC 264; 42 USC 271 
Legal Deadline:  None

Statement of Need: Donor screening and testing, although crucial, are not sufficient to prevent the transmission of disease through HCT/Ps. Each step in the manufacturing process needs to be controlled. Errors in labeling and testing records, failure to adequately clean work areas, and faulty packaging are examples of improper practices that could lead to a product capable of transmitting disease to a recipient. The agency is concerned about the spread of communicable disease through the use of such products. CGTP requirements are a fundamental component of FDA's risk-based approach to regulating HCT/Ps.

Summary of the Legal Basis: The Public Health Service Act (42 U.S.C. 264) authorizes FDA to promulgate regulations to prevent the spread of communicable diseases. HCT/Ps may transmit communicable diseases. The CGTP regulations are essential to the prevention of communicable disease transmission.

Alternatives: An alternative to the proposed approach would be to continue with the use of voluntary industry standards. Reliance on industry's voluntary standards for good tissue practice, rather than establishing regulatory requirements, would not ensure uniform or consistent compliance and would preclude the agency's ability to effectively monitor HCT/Ps to ensure public health and safety.

Anticipated Costs and Benefits: FDA has estimated that this rule would impose a total annualized cost of about $8 million for the entire industry. The primary beneficiaries of the proposed CGTP would be the patients who receive HCT/Ps. Benefits to patients would result from the reduced risk of communicable disease by avoiding product contamination through CGTP.

Risks: FDA believes that the risks posed by requiring CGTP are minimal. In contrast, failure to reduce the risk of transmission of communicable disease through the use of HCT/Ps would jeopardize the public health.

Timetable:
Action Date FR Cite
NPRM  01/08/2001  66 FR 1508 
NPRM Comment Period End  05/08/2001   
Final Action  12/00/2004   
Regulatory Flexibility Analysis Required: Yes  Government Levels Affected: State 
Small Entities Affected: Businesses  Federalism: No 
Included in the Regulatory Plan: Yes 
Agency Contact:
Paula S. McKeever
Senior Scientific Policy Analyst
Department of Health and Human Services
Food and Drug Administration
Suite 200N (HFM-17), Office of the Commissioner, Office of Critical Path Programs, 5600 Fishers Lane, Room 14B-45,
Rockville, MD 20857-0001
Phone:301 827-1520
Fax:301 443-9718
Email: paula.mckeever@fda.hhs.gov

 
About Us   Vertical Spacer Spacer Related Resources   Vertical Spacer Spacer Disclosure   Vertical Spacer Spacer Accessibility   Vertical Spacer Spacer Privacy Policy   Vertical Spacer Spacer Contact Us